Low-Dose Naltrexone for Cancer Pain: Dosing, Evidence, and Safety with Chemotherapy and Hormonal Therapies
Low-dose naltrexone (LDN) is being studied off-label for refractory cancer-related pain. This article reviews typical dosing, early clinical evidence, and key safety considerations for people on chemotherapy or hormonal therapy.
Newly Diagnosed With Prostate Cancer: Should You Consider LDN as Part of Your Treatment Plan?
A prostate cancer diagnosis brings many decisions at once. This article reviews what the early evidence says about low-dose naltrexone (LDN) and what newly diagnosed patients should know before talking to their oncologist.
